This HTML5 document contains 140 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
n11http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q53337715
rdf:type
wikibase:Item
schema:description
2000年學術文章 2000年学术文章 artikel ilmiah מאמר מדעי επιστημονικό άρθρο bilimsel makale tieteellinen artikkeli articolo scientifico artikull shkencor vetenskaplig artikel 2000年學術文章 scienca artikolo სამეცნიერო სტატია 2000年学术文章 مقالة علمية نشرت في أبريل 2000 naučni članak artigo científico artykuł naukowy vitskapeleg artikkel 2000年學術文章 บทความทางวิทยาศาสตร์ artigo científico im April 2000 veröffentlichter wissenschaftlicher Artikel научни чланак научни чланак tudományos cikk article scientific wüsseschaftlicher Artikel, wo im April 2000 veröffentlicht worden isch article científic научная статья vědecký článek artículu científicu teaduslik artikkel vitenskapelig artikkel artículo científico publicado en 2000 scientific article published in April 2000 articol științific наукова стаття, опублікована у квітні 2000 article scientifique 2000年学术文章 2000年學術文章 এপ্রিল ২০০০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ мақолаи илмӣ wetenschappelijk artikel artikulong pang-agham scientific article published in April 2000 bài báo khoa học научна статия 2000 nî lūn-bûn 2000年學術文章 2000年学术文章 2000年学术文章 2000년 논문 videnskabelig artikel artigo científico 2000年の論文 vedecký článok scientific article published in April 2000 2000年学术文章
p:P577
wds:Q53337715-CFD64E8B-1904-4F22-8A8E-08602CC6A095
wdt:P577
2000-04-01T00:00:00Z
p:P407
wds:Q53337715-EEBB0C82-B170-485C-B095-9735D73C7564
wdt:P407
wd:Q1860
p:P2093
wds:Q53337715-44E3F019-1CEC-42E3-9BB7-D79421ABB5BC wds:Q53337715-3D5EC33A-9A3A-4D40-930D-16CD7E1B2B2C wds:Q53337715-3FD72326-F647-403B-8C82-9923093CC3E6 wds:Q53337715-23CD0F1C-18ED-4112-ABA3-287A9549E941 wds:Q53337715-20EC1F04-493B-4654-A3D9-1939004994DE wds:Q53337715-F86753B8-D366-4EE5-8097-B71C59A688DD wds:Q53337715-FF669058-7AF5-4EF2-B05C-2CD0ED96A95B wds:Q53337715-F29066AC-ADC7-4D41-8840-88768AAE1E7B wds:Q53337715-DE9E0B9A-42F8-4FC5-AFCC-3E693C19B909 wds:Q53337715-D2568FAA-CBA0-4849-A7C8-2F4C1113B01E wds:Q53337715-CF6A8CE2-7975-498E-8981-E412D9AA1957 wds:Q53337715-C7C3B6A1-B40D-4021-8837-F7CDA3D9905F wds:Q53337715-A7705362-1716-4490-92B9-7461DCAE64C8 wds:Q53337715-AA7AAB65-3873-4906-A2AA-454FE5ABBD8B wds:Q53337715-A2945F85-ED1B-4F99-ADB9-9FC97EA96F6E wds:Q53337715-5CF228DB-503D-4845-AA4B-60A93788D8D4 wds:Q53337715-6EF12364-E199-4D5D-B8F0-42C346AE7F2F wds:Q53337715-57657989-C211-43F6-9727-9A7C6014BD61 wds:Q53337715-488FC8CC-3872-45EA-B4C9-552FC8F2C44D wds:Q53337715-4EF0B2CB-EA43-4D56-A74F-20C30B8BDF97
wdt:P2093
A S Coates E Simoncini M Bonetti J Bernhard K N Price A Goldhirsch H Cortes-Funes A Gudgeon H J Senn J Lindtner M Castiglione-Gertsch J Forbes A Veronesi C Hürny C M Rudenstam R D Gelber M Fey D Crivellari B Thürlimann J Collins
rdfs:label
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
skos:prefLabel
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
schema:name
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
p:P50
wds:Q53337715-E138A66E-09CC-4EEE-83AA-8FCC5567C00A
wdt:P50
wd:Q120654
p:P1476
wds:Q53337715-E3BD3428-68EF-44C7-9E1C-F286CF3DB588
wdt:P1476
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
p:P304
wds:Q53337715-47F93EBB-0268-4464-8DD7-7DB98A799227
wdt:P304
1412-1422
p:P31
wds:Q53337715-CB6A27A0-D7DA-41FA-9E8F-BCD44CCB9684
wdt:P31
wd:Q13442814
p:P921
wds:Q53337715-E5C1F476-F8A8-487B-BE04-87B57D920A02 wds:Q53337715-D3B1A25A-B779-4D62-95FF-927C35479729 wds:Q53337715-E2603062-DDB1-4446-A27D-C1F86D835EB8 wds:Q53337715-F2570EC1-DBE7-4A59-87E1-337A6FFAD7F9 wds:Q53337715-97D288AE-7350-46F4-9DF2-97991DB7FD94
wdt:P921
wd:Q422232 wd:Q238512 wd:Q181600 wd:Q412178 wd:Q128581
p:P698
wds:Q53337715-2678ED7B-FAF5-4E0D-AAFB-389E5416E0A5
wdtn:P698
n12:10735888
wdt:P698
10735888
p:P1433
wds:Q53337715-CC230A09-2F77-4ECC-9EE3-6C2E38786F12
wdt:P1433
wd:Q400292
p:P433
wds:Q53337715-4EF74A3A-DF39-44BA-96C7-6A26E3B90186
p:P478
wds:Q53337715-E32FC496-2C7E-4AC4-A1D1-CC1D0FB6ACC1
wdt:P433
7
wdt:P478
18
p:P356
wds:Q53337715-12A4DDB7-94F9-4BCC-AD4C-4677AF64A034
wdtn:P356
n11:JCO.2000.18.7.1412
wdt:P356
10.1200/JCO.2000.18.7.1412